Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—ThyroSeq, a joint partnership between UPMC and CBLPath, announced the results of a double-blind, multicenter international study validating the performance of ThyroSeq V3 in thyroid nodules with indeterminate cytology. The results were presented at the 87th Annual Meeting of the American Thyroid Association, Oct. 18–22, in Victoria, British Columbia, Canada.
December 2017—Vector Laboratories introduced the ImmPress Duet Double-Staining Polymer Kit for immunohistochemistry. The kit enables fast, well-defined localization and visualization of two different target antigens on the same tissue section.
December 2017—Agena Bioscience announced a comparative study published in PLOS One (Sutton BC, et al. 2017;12[9]:e0183715) highlighting the use of its mass-spectrometry-based platform and iPlex HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer.
December 2017—Prometheus Laboratories introduced Prometheus Monitr Crohn’s Disease, a serum test that measures and monitors mucosal healing status in Crohn’s disease patients. The test can be used as an adjunct to endoscopy or by itself, between endoscopies, allowing for more frequent, noninvasive monitoring.
December 2017—Streck and Orgentec Sasu, a distributor in France that specializes in the in vitro diagnosis of autoimmunity, infectious diseases, molecular biology, internal/external quality control, biochemistry, and sedimentation rate, have signed an exclusive distribution agreement for Streck’s cell stabilization and molecular products.
December 2017—Binding Site’s Immunologicals Group has added eight recombinant antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The recombinant Parvovirus NS1, Parvovirus VP1, Parvovirus VP2, Parvovirus VP2-VLP, Parvovirus PepA (VP1 unique), Parvovirus PepB (VP2 C-term), Parvovirus PepC (VP1 N-term), and Parvovirus PepD (VP1 C-term) have been designed for use as an integral component within solid phase enzyme immunoassay test procedures, including ELISA.
December 2017—Horizon Discovery’s Dharmacon announced the launch of its CRISPR activation reagent platform, the latest addition to the company’s Edit-R portfolio for CRISPR-Cas9 genome engineering.
December 2017—Chembio Diagnostics received FDA emergency use authorization for its DPP Zika System. The system, for use in high- and moderate-complexity CLIA-certified laboratories, provides results in 15–20 minutes from 10 µL of blood and includes the DPP Zika IgM Assay and DPP Micro Reader.
December 2017—Beckman Coulter Diagnostics announced its Access 2 immunoassay system is available with enhanced features that aim to improve ease of use, workflow efficiencies, system reliability, and customer satisfaction.
December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.
